Skip to content
Disclosery

Patient Square Capital LP

Follow

13F filer, CIK 1819257, MENLO PARK, CA

Patient Square Capital LP reported $563,607,117 across 29 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-15. Its ten largest share positions make up 73.28% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001819257-26-000003

Period
2026-03-31
Reported value
$564M
Holdings
29
Top 10 weight
73.28%
New
7
Sold out
6

Largest buys vs the previous quarter

SecurityShares changeApprox. value
BLTEnew+116,684$18.6M
LEGNnew+990,000$17.9M
NKTRnew+210,000$15.1M
COGTadded+278,628$10.7M
MRKnew+80,000$9.62M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
INSMreduced-109,500-$17.9M
TERNexited-320,000-$12.9M
LQDAexited-227,000-$7.83M
SYREreduced-149,000-$7.52M
MIRMreduced-68,682-$6.34M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001819257-26-000003, largest first. % of portfolio is the value over $563,607,117, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ROIVROIVANT SCIENCES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 12,228,465 shares; 2024Q4: 12,480,000 shares; 2025Q1: 12,480,000 shares; 2025Q2: 12,480,000 shares; 2025Q3: 12,480,000 shares; 2025Q4: 8,166,047 shares; 2026Q1: 8,166,047 shares 8,166,047$226M40.13%0Timeline
ARGXARGENX SEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 29,000 shares; 2025Q3: 15,500 shares; 2025Q4: 26,000 shares; 2026Q1: 36,718 shares 36,718$26.8M4.76%+10,718Timeline
INSMINSMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 171,704 shares; 2024Q4: 307,167 shares; 2025Q1: 330,250 shares; 2025Q2: 358,800 shares; 2025Q3: 326,400 shares; 2025Q4: 267,000 shares; 2026Q1: 157,500 shares 157,500$25.8M4.57%-109,500Timeline
ONCBEONE MEDICINES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 69,312 shares; 2026Q1: 80,542 shares 80,542$23.9M4.24%+11,230Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 317,372 shares; 2026Q1: 596,000 shares 596,000$22.9M4.07%+278,628Timeline
MIRMMIRUM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 64,900 shares; 2025Q1: 116,362 shares; 2025Q2: 113,462 shares; 2025Q3: 104,262 shares; 2025Q4: 298,682 shares; 2026Q1: 230,000 shares 230,000$21.2M3.77%-68,682Timeline
BLTEBELITE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 116,684 shares 116,684$18.6M3.3%newTimeline
LEGNLEGEND BIOTECH CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 990,000 shares 990,000$17.9M3.18%newTimeline
NKTRNEKTAR THERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 210,000 shares 210,000$15.1M2.68%newTimeline
DBVTDBV TECHNOLOGIES S AQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 359,050 shares; 2026Q1: 693,534 shares 693,534$14.5M2.57%+334,484Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 242,341 shares; 2024Q4: 207,603 shares; 2025Q1: 245,496 shares; 2025Q2: 244,283 shares; 2025Q3: 345,381 shares; 2025Q4: 542,696 shares; 2026Q1: 493,000 shares 493,000$13.9M2.47%-49,696Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 151,833 shares; 2025Q4: 130,000 shares; 2026Q1: 121,245 shares 121,245$13.5M2.4%-8,755Timeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 136,500 shares; 2026Q1: 227,000 shares 227,000$13.2M2.34%+90,500Timeline
CELCCELCUITY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 100,000 shares; 2025Q4: 120,000 shares; 2026Q1: 95,000 shares 95,000$10.8M1.92%-25,000Timeline
EYPTEYEPOINT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,361,979 shares; 2024Q4: 1,410,331 shares; 2025Q1: 1,481,977 shares; 2025Q2: 1,352,837 shares; 2025Q3: 1,011,839 shares; 2025Q4: 780,000 shares; 2026Q1: 795,000 shares 795,000$10.2M1.82%+15,000Timeline
MRKMERCK & CO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 80,000 shares 80,000$9.62M1.71%newTimeline
ARQTARCUTIS BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 210,000 shares; 2026Q1: 400,645 shares 400,645$9.44M1.67%+190,645Timeline
ALLOALLOGENE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 1,489,909 shares; 2025Q1: 2,368,186 shares; 2025Q2: 2,635,000 shares; 2025Q3: 2,981,396 shares; 2025Q4: 4,963,756 shares; 2026Q1: 3,450,000 shares 3,450,000$8.42M1.49%-1,513,756Timeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 142,201 shares; 2025Q2: 140,000 shares; 2025Q3: 92,592 shares; 2025Q4: 139,000 shares; 2026Q1: 100,000 shares 100,000$8.33M1.48%-39,000Timeline
DNTHDIANTHUS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 125,000 shares; 2025Q4: 150,000 shares; 2026Q1: 93,882 shares 93,882$7.88M1.4%-56,118Timeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 90,572 shares; 2024Q4: 224,038 shares; 2025Q1: 253,838 shares; 2025Q2: 245,838 shares; 2025Q3: 250,838 shares; 2025Q4: 308,141 shares; 2026Q1: 200,000 shares 200,000$7.84M1.39%-108,141Timeline
CATXPERSPECTIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 349,323 shares; 2025Q4: 1,132,815 shares; 2026Q1: 1,625,000 shares 1,625,000$6.78M1.2%+492,185Timeline
DFTXDEFINIUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 331,000 shares 331,000$6.26M1.11%newTimeline
HROWHARROW INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 7,031 shares; 2026Q1: 165,209 shares 165,209$5.83M1.03%+158,178Timeline
TARAPROTARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,030,846 shares 1,030,846$5.37M0.95%newTimeline
CTMXCYTOMX THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,085,790 shares 1,085,790$5.1M0.91%newTimeline
RCUSARCUS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 170,000 shares; 2026Q1: 195,000 shares 195,000$4.21M0.75%+25,000Timeline
ASMBASSEMBLY BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 135,182 shares; 2025Q4: 127,000 shares; 2026Q1: 136,315 shares 136,315$3.78M0.67%+9,315Timeline
SYRESPYRE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 150,000 shares; 2026Q1: 1,000 shares 1,000$50.4K0.01%-149,000Timeline

Sold out in Q1 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
TERNTERNS PHARMACEUTICALS INC320,000$12.9Mshares
LQDALIQUIDIA CORPORATION227,000$7.83Mshares
OCULOCULAR THERAPEUTIX INC490,000$5.95Mshares
IRONDISC MEDICINE INC74,000$5.88Mshares
AVTXAVALO THERAPEUTICS INC311,966$5.67Mshares
AMLXAMYLYX PHARMACEUTICALS INC350,000$4.23Mshares

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001819257-26-000003 base2026-05-15acceptance time not in the bulk data set